Shira Gabizon Peretz, MD
Research Fellow, Kluger LabAbout
Research
Publications
Featured Publications
Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective
Gabizon A, Gabizon-Peretz S, Modaresahmadi S, La-Beck N. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. BMJ Oncology 2025, 4: e000573. PMID: 39885941, PMCID: PMC11751825, DOI: 10.1136/bmjonc-2024-000573.Peer-Reviewed Original ResearchPegylated Liposomal DoxorubicinLiposomal doxorubicinClinical approvalFDA approvalCancer therapyRelapsed ovarian cancerMetastatic breast cancerReduction of cardiotoxicityFood and Drug AdministrationImmune modulatory propertiesImpressive reductionMultimodal therapyAdjuvant therapyOvarian cancerBreast cancerEPR effectNano-drugsPharmacological principlesDrug AdministrationTherapyHuman cancersCancerModulatory propertiesComplement systemClinical applicationEmergent Pulmonary Hypertension and Right Ventricular Impairment Following Gemcitabine Therapy for Metastatic Breast Cancer.
Gabizon-Peretz S, Yerushalmi R, Vaturi M, Nardi Agmon I. Emergent Pulmonary Hypertension and Right Ventricular Impairment Following Gemcitabine Therapy for Metastatic Breast Cancer. Israel Medical Association Journal 2025, 27: 319-321. PMID: 40365974.Peer-Reviewed Original ResearchResults of the TARGET-TP Randomized Clinical Trial
Gabizon S, Eizenstein S, Meirson T. Results of the TARGET-TP Randomized Clinical Trial. JAMA Oncology 2024, 10: 988-988. PMID: 38814593, DOI: 10.1001/jamaoncol.2024.0113.Peer-Reviewed Original ResearchBreast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy
Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. European Journal Of Cancer 2021, 148: 95-102. PMID: 33743487, DOI: 10.1016/j.ejca.2021.02.007.Peer-Reviewed Original ResearchConceptsRisk-Reducing Salpingo-OophorectomyHealthy BRCA1/2 mutation carriersHormone replacement treatmentBRCA1/2 mutation carriersBC riskMutation carriersHRT useBreast cancerShort-term HRT useSalpingo-oophorectomyBreast cancer riskRisk of BCEffect of hormone replacement treatmentHRT groupNatural age of menopauseBRCA1/BRCA2 mutation carriersBC ratesHormone replacement therapyNon-HRT groupBC incidenceBRCA1/BRCA2 carriersAge of menopauseBRCA1/2 carriersBRCA carriersCancer risk